日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

INBRX-109(一种第三代重组人源化死亡受体5激动剂抗体)在软骨肉瘤中的临床前表征和I期试验结果

Vivek Subbiah ,Sant P Chawla ,Anthony P Conley ,Breelyn A Wilky ,Anthony Tolcher ,Nehal J Lakhani ,David Berz ,Vasily Andrianov ,William Crago ,Monica Holcomb ,Abrahim Hussain ,Carson Veldstra ,James Kalabus ,Brianne O'Neill ,Lane Senne ,Emily Rowell ,Analeah B Heidt ,Katelyn M Willis ,Brendan P Eckelman

Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma

贝培格地白介素与纳武单抗联合治疗转移性肉瘤患者的初步研究

Sandra P D'Angelo #, Allison L Richards #, Anthony P Conley, Hyung Jun Woo, Mark A Dickson, Mrinal Gounder, Ciara Kelly, Mary Louise Keohan, Sujana Movva, Katherine Thornton, Evan Rosenbaum, Ping Chi, Benjamin Nacev, Jason E Chan, Emily K Slotkin, Hannah Kiesler, Travis Adamson, Lilan Ling, Pavitra

Synergistic induction of apoptosis by the Bcl-2 inhibitor ABT-737 and imatinib mesylate in gastrointestinal stromal tumor cells

Bcl-2抑制剂ABT-737与甲磺酸伊马替尼对胃肠道间质瘤细胞凋亡的协同诱导作用

David Reynoso, Laura K Nolden, Dan Yang, Sarah N Dumont, Anthony P Conley, Amaury G P Dumont, Kim Zhou, Anette Duensing, Jonathan C Trent